Similar articles for PMID: 34732447

Year	Number of Results
2015	1
2016	4
2017	11
2018	32
2019	37
2020	67
2021	131
2022	102
2023	28

1

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.

Shimoda Y, Yoshida T, Shirasawa M, Mizuno T, Jo H, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y, Motoi N. Shimoda Y, et al. Anticancer Res. 2021 Nov;41(11):5739-5747. doi: 10.21873/anticanres.15390. Anticancer Res. 2021. PMID: 34732447

2

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.

Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685 Free article.

3

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Haratani K, et al. Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183. Ann Oncol. 2017. PMID: 28407039 Free article.

4

Tumor mutational load, CD8⁺ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.

Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Thüsen JH, van der Burg SH. Hurkmans DP, et al. Cancer Immunol Immunother. 2020 May;69(5):771-777. doi: 10.1007/s00262-020-02506-x. Epub 2020 Feb 12. Cancer Immunol Immunother. 2020. PMID: 32047958 Free PMC article.

5

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.

Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X, Huang Z, Fan Y. Chen K, et al. Lung Cancer. 2020 Apr;142:98-105. doi: 10.1016/j.lungcan.2020.02.010. Epub 2020 Feb 19. Lung Cancer. 2020. PMID: 32120230

6

Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.

Nojima Y, Shimizu K, Saisho S, Maeda AI, Kurosaki T, Kurose K, Oga T, Oka M, Nakata M. Nojima Y, et al. Anticancer Res. 2021 Nov;41(11):5469-5475. doi: 10.21873/anticanres.15359. Anticancer Res. 2021. PMID: 34732416

7

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.

Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ochi N, et al. Eur J Cancer. 2021 May;149:73-81. doi: 10.1016/j.ejca.2021.02.040. Epub 2021 Apr 7. Eur J Cancer. 2021. PMID: 33838391

8

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.

El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M. El-Guindy DM, et al. J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. doi: 10.1016/j.jnci.2018.08.003. Epub 2018 Oct 15. J Egypt Natl Canc Inst. 2018. PMID: 30337185 Free article.

9

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.

Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J. Gataa I, et al. Eur J Cancer. 2021 Mar;145:221-229. doi: 10.1016/j.ejca.2020.10.017. Epub 2021 Jan 27. Eur J Cancer. 2021. PMID: 33516050

10

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.

Teng F, Meng X, Wang X, Yuan J, Liu S, Mu D, Zhu H, Kong L, Yu J. Teng F, et al. Oncotarget. 2016 Sep 27;7(39):64318-64329. doi: 10.18632/oncotarget.11793. Oncotarget. 2016. PMID: 27602763 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

358 results

Results by year